Extedo adds two to management board

Directors will be based in Germany and US respectively

Extedo, a provider of eRegulatory Affairs solutions to life sciences firms, has added Martin Schmid and Joseph Dude to its management board.

Schmid joins the organisation as president and now shares day-to-day operational responsibilities with chief executive Tore Bergsteiner.

Dude has taken the position of managing director at Extedo Inc in the US, to support the organisation’s expansion in North America.

Schmid will head up the global marketing and sales organisation as well as the Product Management Unit, which are key areas for Extedo. He will be based in Ottobrunn, Germany.

Schmid has more than 15 years of experience in management consulting, marketing and sales.

Dude will be based in West Chester, PA. He has more than 20 years of experience in the IT services and software industries with Prime Technology Group, Glemser Technologies, First Consulting Group and Thomson Financial.

You may also like

Regulatory

Amcor’s Winterbourne site achieves ISO 13485 certification, strengthening its position and capabilities in healthcare

ISO 13485:2016 is an internationally recognised quality management standard specifically for medical devices.
Regulatory

Roche wins CE mark for first blood-based immunoassay to identify ApoE4 Alzheimer's risk variant

Roche's Elecsys ApoE4 test has received CE mark approval as the first in-vitro diagnostic immunoassay to detect the ApoE4 genetic variant from a simple blood sample, potentially eliminating the need for confirmatory DNA testing in Alzheimer's patients who do not carry the variant
Regulatory

Orphan drug sales to exceed $400bn by 2032, Evaluate report finds

Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
Regulatory

Shilpa Biologicals and mAbTree secure FDA Orphan Drug Designation for rare blood cancer biologic

The FDA has granted Orphan Drug Designation to the pair's investigational monoclonal antibody for Essential Thrombocythemia and Polycythemia Vera, two rare chronic blood cancers with significant unmet treatment need
Media

CBA releases statement welcoming government's decision to incude biocides in post-Brexit negotiations

Biocides have now been officially included in the scope of negotiations, which the association has called an "important and practical step towards cutting red tape and restoring clarity for businesses," though the "reality is that much more still needs to be done"
Manufacturing

Lonza and Genetix extend commercial manufacturing agreement for ZYNTEGLO™

Expanded collaboration will support growing demand for FDA-approved gene therapy for beta-thalassemia
Regulatory

Orbia Fluor & Energy Materials registers US DMF file for low-GWP propellant

The fluor-based product manufacturer announced the creation of a US Type IV Drug Master File (DMF) for the low-GWP excipient Zephex 152a, with pharma companies now able to reference the data package for faster, lower-risk FDA reviews for pMDIs
Subscribe now